Utah Medical Products Inc (UTMD): who owns it and who trades it
As of Nov 16, 2026, UTMD insiders reported 1 purchase worth $66.8K in the last 12 months. The largest buyer was Kevin L Cornwell (CEO), with $66.8K. 2 of the 50 famous funds we follow held it at their last quarter end.
Latest filing Nov 16, 2026. From Form 4, 13F and Schedule 13D/G filings.
At a glance
Who is buying and selling Utah Medical Products
From the latest filingsOverall: more buying than selling. Insiders mostly bought. Funds and famous investors were close to even.
Each group counts equally in the meter, by the number of buyers and sellers, not dollars. Insider sales under pre-set 10b5-1 plans are left out of it. From SEC, House and Senate filings; not advice.
Who owns UTMD
114 funds and institutions reported UTMD shares worth $161M at the end of Q2 2026, about 73% of the company. The largest holder is Brandes Investment Partners, LP with 14.9%.
Funds and institutions (13F) 73%Everyone else 27%
10 largest owners, by share of the company
Top 20 owners
| Owner | Shares | % of company | Value | Change since Q1 2026 |
|---|---|---|---|---|
| Brandes Investment Partners, LP | 475,158 | 14.92% | $32.8M | +6% |
| BlackRock, Inc. | 203,690 | 6.40% | $14.1M | +9% |
| Dimensional Fund Advisors LP | 198,817 | 6.24% | $13.7M | +0% |
| Renaissance Technologies LLC | 175,814 | 5.52% | $12.1M | -5% |
| Vanguard Capital Management LLC | 134,535 | 4.22% | $9.3M | -3% |
| Geode Capital Management, LLC | 108,048 | 3.39% | $7.5M | -10% |
| Minerva Advisors LLC | 93,615 | 2.94% | $6.5M | No change |
| Hotchkis & Wiley Capital Management LLC | 85,231 | 2.68% | $5.9M | -4% |
| Rice Hall James & Associates, LLC | 71,363 | 2.24% | $4.9M | +5% |
| Morgan Stanley | 69,671 | 2.19% | $4.8M | +43% |
| State Street Corp | 63,937 | 2.01% | $4.4M | -1% |
| Quantinno Capital Management LP | 43,074 | 1.35% | $3M | +44% |
| UBS Group AG | 34,369 | 1.08% | $2.4M | -7% |
| Bank of New York Mellon Corp | 34,263 | 1.08% | $2.4M | +7% |
| Northern Trust Corp | 30,104 | 0.95% | $2.1M | -1% |
| Huber Capital Management LLC | 29,009 | 0.91% | $2M | -19% |
| Cardinal Capital Management | 27,094 | 0.85% | $1.9M | +2% |
| Everett Harris & Co | 23,933 | 0.75% | $1.7M | -6% |
| T. Rowe Price Associates | 21,938 | 0.69% | $1.5M | +20% |
| O'shaughnessy Asset Management, LLC | 21,683 | 0.68% | $1.5M | +2% |
From the SEC 13F data sets: every fund manager with over $100M must report its US stock holdings every 3 months, up to 45 days after the quarter ends. Owners are shown as they file, so one group (for example Vanguard) can appear under several names. Individuals, most insiders and smaller funds do not file 13F reports.
Insider trades
In the last 12 months, UTMD insiders reported $66.8K of open-market purchases and $0 of sales.
Purchases and sales by month
Latest trades
| Date | Insider | Role | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|---|
| Oct 29, 2026 | Kevin L Cornwell | CEO | Purchase | 1,000 | $66.75 | $66.8K | Form 4 |
Insiders by value traded
| Insider | Role | Bought | Sold | Last trade |
|---|---|---|---|---|
| Kevin L Cornwell | Chairman, CEO, Director | $66.8K | – | Oct 29, 2026 |
What this data shows, and what it doesn't
- Shows: open-market purchases and sales by officers, directors and 10%+ owners, reported on Form 4 within two business days of the trade.
- Leaves out: stock awards, option exercises, shares withheld for tax and gifts. These are not trades at a market price chosen by the insider.
- "plan" marks a sale made under a Rule 10b5-1 plan, a schedule set up in advance.
- Fund holders come from 13F reports, a snapshot at quarter end filed up to 45 days later.
- Filings are self-reported and can be amended. Each trade links to its original filing. Methodology
UTMD short interest
Low short interest. 4.8% of UTMD shares are sold short: about 1 share in 21. Over the last 12 reports the number of shares short went up 14%.
As a rough guide, under 5% is low, 5–10% is moderate, 10–20% is high and over 20% is very high.
As of Oct 30, 2026, 151,293 UTMD shares were sold short, 4.8% of the shares outstanding, up 7.9% from the report before. At the average daily volume of 38,807 shares, buying them all back would take about 3.9 trading days (days to cover).
Shares short, % of all shares
Days to cover
Every report
| Settlement date | Shares short | % of shares | Change | Avg daily volume | Days to cover |
|---|---|---|---|---|---|
| Oct 30, 2026 | 151,293 | 4.75% | +8% | 38,807 | 3.9 |
| Oct 15, 2026 | 140,215 | 4.40% | -8% | 39,123 | 3.6 |
| Sep 30, 2026 | 151,912 | 4.77% | -12% | 31,690 | 4.8 |
| Sep 15, 2026 | 172,180 | 5.41% | +3% | 38,025 | 4.5 |
| Aug 31, 2026 | 166,805 | 5.24% | +19% | 41,441 | 4.0 |
| Aug 14, 2026 | 139,715 | 4.39% | +3% | 19,857 | 7.0 |
| Jul 31, 2026 | 135,579 | 4.26% | -3% | 40,220 | 3.4 |
| Jul 15, 2026 | 140,086 | 4.40% | +1% | 18,155 | 7.7 |
| Jun 30, 2026 | 138,696 | 4.35% | +6% | 20,418 | 6.8 |
| Jun 15, 2026 | 131,133 | 4.12% | +16% | 8,588 | 15.3 |
| May 29, 2026 | 113,014 | 3.55% | -15% | 11,989 | 9.4 |
| May 15, 2026 | 132,672 | 4.17% | +5% | 8,620 | 15.4 |
Short sellers borrow shares and sell them, hoping to buy them back for less. A high number means many such bets are open. It does not say where the price will go. Source: FINRA equity short interest, reported by brokers twice a month (positions on the 15th and the last business day) and published about 7 business days later. % of shares uses the share count on the company's latest SEC filing. What short interest means · Most shorted stocks
Utah Medical Products company events
Utah Medical Products filed 7 reports on Form 8-K in the last 12 months, all of them routine, such as results and vote reports. The latest was on Nov 3, 2026.
- Nov 3, 2026AnnouncementUtah Medical Products, Inc. announced that it is increasing its regular quarterly cash dividend. Filing
- Oct 22, 2026ResultsReleased financial results. Filing
- Aug 31, 2026AnnouncementShared information with investors. Filing
- Jul 23, 2026ResultsReleased financial results. Filing
- May 4, 2026VoteReported shareholder vote results. Filing
- Apr 23, 2026ResultsReleased financial results. Filing
- Jan 29, 2026ResultsReleased financial results. Filing
From 8-K reports, which a company must file within 4 business days of an important event. Where a report is about a change such as a new CEO, the sentence is the first one from the report itself, shortened. Each row links to the original filing. Company events this week
Utah Medical Products financials
Famous investors that hold UTMD
2 of the 50 well-known investors we track reported holding UTMD in their latest 13F filing. The largest position is Jim Simons's, worth $12.4M.
| Fund | Quarter | Shares | Value | Of portfolio | Change |
|---|---|---|---|---|---|
| Jim Simons · Renaissance Technologies | Q3 2026 | 167,514 | $12.4M | 0.0% | -5% |
| Ken Griffin · Citadel Advisors | Q3 2026 | 13,904 | $1M | 0.0% | New |
From 13F reports: a snapshot at quarter end, filed up to 45 days later. Change compares with the quarter before.
Questions about Utah Medical Products Inc (UTMD) stock
Who owns the most UTMD stock?
The largest reported owner of Utah Medical Products Inc (UTMD) is Brandes Investment Partners, LP, with 14.9% of the company. In total, 114 funds and institutions reported holding UTMD at the end of Q2 2026, together about 73% of the shares. See the largest owners.
Are UTMD insiders buying or selling?
In the last 12 months, UTMD insiders reported 1 open-market purchase worth $66.8K and no sales. The latest trade was on Oct 29, 2026. See every trade.
What is the short interest in UTMD?
As of Oct 30, 2026, 151,293 UTMD shares were sold short, 4.8% of the shares outstanding, up 7.9% from the report before. At the average daily volume of 38,807 shares, buying them all back would take about 3.9 trading days (days to cover). See the history.
Which famous investors hold UTMD?
2 of the 50 well-known investors we track reported UTMD in their latest 13F filing, including Jim Simons, Ken Griffin. The largest position is worth $12.4M. See all holders.
Source: SEC Form 4 (insiders, filed within 2 business days), 13F (funds, up to 45 days after quarter end) and Schedule 13D/13G filings. Only open-market purchases (code P) and sales (code S) are shown. Data only, not investment advice. How we collect it.